milrinone has been researched along with Cardiac Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| St-Pierre, P | 1 |
| Deschamps, A | 1 |
| Cartier, R | 1 |
| Basmadjian, AJ | 1 |
| Denault, AY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Paceport Swan-Ganz Data Collection Study[NCT04782154] | 136 participants (Actual) | Observational | 2021-08-09 | Completed | |||
| Validation of Cerebral Non-invasive Monitoring and Prediction of Post-operative Delirium and Outcomes: A Prospective Observational Study[NCT04643834] | 151 participants (Anticipated) | Observational | 2019-11-21 | Recruiting | |||
| Early Identification and Prediction of Right Ventricular Dysfunction and Failure in Critically Ill Patients: An Observational Non-Interventional Cohort Study[NCT04092855] | 112 participants (Anticipated) | Observational | 2018-12-10 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for milrinone and Cardiac Cancer
| Article | Year |
|---|---|
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |
Inhaled milrinone and epoprostenol in a patient with severe pulmonary hypertension, right ventricular failure, and reduced baseline brain saturation value from a left atrial myxoma.
Topics: Administration, Inhalation; Adult; Antihypertensive Agents; Brain Chemistry; Cardiac Surgical Proced | 2014 |